Health & Wellbeing Education & Young People 2024
Cure Parkinson's

Annual Report and Financial Statements 2024-25

Cure Parkinson's 2024-25 annual report marks the charity's 20th year, covering a transformative period in its research funding. Highlights include a £5.7m commitment to EJS ACT-PD — the UK's first multi-arm multi-stage Parkinson's trial platform — and the opening of recruitment for the ASPro-PD phase 3 ambroxol trial. Nine new projects were funded across clinical, preclinical and observational research, with cumulative research investment now exceeding £25.4m. Reserves grew to £10.8m for the first time, giving the charity the financial agility to lead on larger, more ambitious programmes. The charity aims to raise and invest a further £20m over the next three years.

View Report
Report snapshot
57 Views

📋About

EJS ACT-PD multi-arm multi-stage clinical trial platform (£5.7m committed, part of £16.1m consortium); ASPro-PD phase 3 ambroxol trial (recruitment opened Feb 2025); SLEIPNIR trial platform (£1.1m committed); DAPA-PD anti-inflammatory phase 2 trial (Cambridge, £1.065m); 9 new projects funded including 3 clinical trials; International Linked Clinical Trials (iLCT) programme; collaboration with Alzheimer's Research UK; policy campaigning via Parky Charter and Neurological Alliance

📊Key Metrics

£8.1m committed to new research projects; 32 active projects worth £18.5m; cumulative research funding exceeds £25.4m since 2005 Key Metric 1
Cure Parkinson's is a UK charity founded in 2005, now in its 20th year, with a singular focus on funding research to slow, stop and reverse Parkinson's. Around 166,000 people in the UK and an estimated 11.8 million globally live with the condition. The charity funds and facilitates research across clinical trials, preclinical studies and drug discovery, working collaboratively with international partners and academic institutions. Key Metric 2
Disease-Modifying Research; Clinical Trials; Drug Repurposing; International Collaboration; Policy & Advocacy Key Metric 3

✅Key Outcomes

  • £8.1m committed to new research in 2024-25; 32 active projects worth £18.5m across 38 institutions in 11 countries; reserves grew to £10.8m enabling larger-scale commitments
  • 9 new projects funded including 3 clinical trials; ASPro-PD opened recruitment Feb 2025; EJS ACT-PD platform — a global first for Parkinson's — set to begin recruiting participants in second half of 2025
  • 11,102 donations received; cumulative research investment exceeds £25.4m across 80 projects since 2005; new collaboration with Alzheimer's Research UK; Parky Charter handed to Downing Street April 2024

📍Geography

UK-Wide

Related reports

All Health & Wellbeing reports →
2026 Enhanced
DEBRA UK

Impact — Winter 2026

Total income £18,180,000 and total expenditure £18,560,000 (year ended 31 December 2024, charity no. 1084958 England/Wales and SC039654 Scotland); in 2024 spent £3.8m on charitable activities including £1,079,000 on research, £1,366,000 on EB Community Support, £943,000 on public education, £270,000 on EB healthcare and £185,000 on respite breaks
Key Metric 1
700+ members supported through in-person visits and support calls in 2025; 697 support grants allocated in 2025 for essential items including specialist clothing, cooling fans and sheepskin liners; 2 new holiday homes purchased in 2025 with over 700 guests enjoying holiday homes; £34,000 raised through 2025 winter 'The Longest Night' appeal
Key Metric 2
Largest global investment in EB research to date: multi-million-pound drug repurposing trial provisionally agreed with LifeArc partner at Guy's and St Thomas' NHS Foundation Trust and King's College London; EB Priorities Setting Partnership study completed mapping global research priorities for all four main EB forms
Key Metric 3
£34,000 raised in 2025 winter appeal supporting families like Darcie's with specialist items, emotional support and research; 697 support grants delivered in 2025; first Members Connect event in Northern Ireland; EB Priorities Setting Partnership study completed providing global research roadmap
Health & Wellbeing Disability
View
2025 Enhanced
The Royal British Legion

Impact Report 2025

22,507 households helped through RBL casework and specialist support services across 66 countries
Key Metric 1
22,600 grants given to those in need, totalling £11.8 million
Key Metric 2
733 beneficiaries represented at tribunals, resulting in £24.5 million in War Pensions awards
Key Metric 3
1,548 new families living with dementia supported by RBL Admiral Nurses service
Health & Wellbeing Dementia
View
2025 Enhanced
Blind Veterans UK

Our Impact 2024-25

3,600 blind veterans received support across the UK; 447 new blind veterans started receiving support in 2024/25
Key Metric 1
1,598 referrals to rehabilitation services completed; 313 veterans received assistive technology training
Key Metric 2
997 volunteers donated 26,824 hours of support; befriending service awarded Quality in Befriending Excellence — one of only 11 organisations in the UK to achieve this
Key Metric 3
1,831 National Creative Wellbeing Project packs issued to help veterans reconnect with creativity and independence
Health & Wellbeing Wellbeing
View